Aimmune Therapeutics, Inc.
Bridgewater, NJ
- UEI
- E3ULPC7MFBK9
- CAGE
- 8H6R2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1007 US-202 206, Bldg, Bridgewater, NJ 08807, USA
- Website
- nestlehealthscience.us
- Founded
- 2012
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Consumer Staples
- Food, Beverage & Tobacco
- Food Products
- Packaged Foods & Meats
- SIC code
- 20 Food & Kindred Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $78,597 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Vowst | Veterans Integrated Service Network 20 (VHA) | $13,100 | |
| Vowst fecal microbiota | Veterans Integrated Service Network 21 (VHA) | $13,100 | |
| Vowst pharmaceutical | Veterans Integrated Service Network 20 (VHA) | $13,100 | |
| Vowst fecal microbiota | Veterans Integrated Service Network 20 (VHA) | $13,100 | |
| Vowst 30000000 CFU | Veterans Integrated Service Network 5 (VHA) | $13,100 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Aimmune Therapeutics, Inc. is a biopharmaceutical company specializing in developing treatments for food allergies, particularly peanut allergies. The company's primary product offered to the federal government is Palforzia, an oral immunotherapy indicated to reduce the severity of allergic reactions to peanuts in children and adolescents. Aimmune Therapeutics has established a strong partnership with the U.S. Department of Veterans Affairs (VA) to provide its innovative treatments through various contract vehicles. These include Federal Supply Schedule (FSS) contracts, Blanket Purchase Agreements (BPAs), and delivery orders, enabling the VA to efficiently acquire pharmaceutical products to support its mission of delivering comprehensive healthcare services to America's veterans.
Through its federal contract awards, Aimmune Therapeutics has consistently provided Palforzia and other pharmaceutical products to various Veterans Integrated Service Networks (VISNs) within the VA healthcare system. The company has received multiple firm-fixed price delivery orders, typically valued at $13,099.50 each, for the supply of Palforzia and other treatments such as VOWST, a fecal microbiota product. These awards have been made by different VISNs, including VISN 5, VISN 20, and VISN 21, demonstrating the widespread use of Aimmune's products across the VA healthcare network. The contracts are generally awarded without set-aside designations, and Aimmune serves as the prime contractor for these specialized pharmaceutical products. In addition to Palforzia, the company has also supplied emergency pharmacy orders and other pharmaceutical products to support VA programs, reflecting its capacity to meet diverse healthcare needs within the veteran population.
Aimmune Therapeutics holds several significant federal contract Indefinite Delivery Vehicles (IDVs) that facilitate the procurement of its products by VA facilities. The company's primary IDV is a multiple-award Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs (FSS-61-IB) category, with a ceiling value of $315,380 and an ultimate completion date of April 14, 2026. This FSS contract allows various VISNs to issue delivery orders for Palforzia and other pharmaceutical products. Additionally, Aimmune has been awarded two single-award Blanket Purchase Agreements (BPAs) by the VA National Acquisition Center specifically for Palforzia. The most recent BPA has a ceiling value of $500,000 and runs through April 14, 2025. A previous BPA, which ended on April 14, 2021, had a higher ceiling value of $14,000,000. These consolidated IDV contracts and BPAs enable the VA to streamline the acquisition of Aimmune's specialized allergy treatments and ensure consistent access to these innovative therapies for veterans and their dependents across multiple VA medical centers nationwide.
Quick answers
Is Aimmune Therapeutics, Inc. registered in SAM.gov?
Aimmune Therapeutics, Inc.'s SAM.gov registration expired on August 25, 2026.
Which contract vehicles does Aimmune Therapeutics, Inc. hold?
Aimmune Therapeutics, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Aimmune Therapeutics, Inc. received in federal contracts?
Federal contracts obligated $78,597 to Aimmune Therapeutics, Inc. in fiscal years 2023 through 2027.
What is Aimmune Therapeutics, Inc.'s most recent federal award?
Aimmune Therapeutics, Inc.'s most recent federal contract award is Vowst (36C26024F0436), from Veterans Integrated Service Network 20 (VHA), on June 5, 2024.
On GovTribe
See Aimmune Therapeutics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors